Trial Profile
Combination of Ibrutinib and As2O3 in the Treatment of CLL
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 05 May 2016 New trial record